AFP and hepatocellular carcinoma: To further evaluate the therapeutic efficacy of oncolytic Ads against HCC, serum levels of AFP, which is a good marker for gauging the malignancy of HCC and disease progression33, were analyzed at the start of treatment and 5 weeks after the initial treatment.